Vaccitech

Vaccitech Limited is a biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, such as hepatitis B, HPV and prostate cancer.[1][2] The company's platform includes Chimpanzee Adenovirus Oxford (ChAdOx) and Modified Vaccinia Ankara (MVA), two viral vectors which mimic viral disease in human cells and elicit T cell responses to pathogens and tumours.[3] The company was founded in 2016 as a University spin-off by Sarah Gilbert and Adrian V. S. Hill at the Jenner Institute, University of Oxford.[4][5][6][7]

Vaccitech Limited
IndustryVaccines
Immunotherapy
Biotechnology
Founded2016 (2016)
Founder
Headquarters
Oxford Science Park, Oxford
,
United Kingdom
Websitevaccitech.co.uk

Vaccitech has been financed and supported by Google Ventures (GV), Sequoia Capital, GeneMatrix, Liontrust Asset Management, Korea Investment Partners and Oxford Sciences Innovation (OSI).[8] As of 2020 investment in vaccitech has included over £20m of series A round funding.[7]

References
  1. Vaccitech on Twitter
  2. Anon (2016). "Vaccitech Limited". companieshouse.gov.uk. London: Companies House.
  3. Anon (2019). "Vaccitech - Creating ways to treat and prevent disease". vaccitech.co.uk. Vaccitech Limited.
  4. Anon (2020). "Company listing". crunchbase.com. Crunchbase. Retrieved 2020-04-24.
  5. Anon (2019). "Vaccitech Ltd". bloomberg.com. Bloomberg News.
  6. Anon (2016). "Universal flu vaccine under development by Oxford spinout Vaccitech". ox.ac.uk. University of Oxford.
  7. Anon (2019). "Vaccitech secures £20m Series A with GV, OSI and Sequoia China". innovation.ox.ac.uk. Oxford University Innovation.
  8. Anon (2019). "About Vaccitech". vaccitech.co.uk. Vaccitech Limited.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.